Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Niraj M Sakhrani & Harish Padh. (2013) Organelle targeting: third level of drug targeting. Drug Design, Development and Therapy 7, pages 585-599.
Read now
Read now
John Costanzi, David Sidransky, Ami Navon & Howard Goldsweig. (2005) Ribonucleases as a Novel Pro-Apoptotic Anticancer Strategy: Review of the Preclinical and Clinical Data for Ranpirnase. Cancer Investigation 23:7, pages 643-650.
Read now
Read now
. (2003) Literature Alerts. Journal of Microencapsulation 20:2, pages 279-287.
Read now
Read now
. (2003) Literature Alerts. Journal of Microencapsulation 20:2, pages 279-287.
Read now
Read now
Franco Muggia. (2002) Stable Disease in Mesothelioma: A Therapeutic Achievement?. Cancer Investigation 20:5-6, pages 859-860.
Read now
Read now
Articles from other publishers (23)
Kageaki Watanabe, Yusuke Okuma, Shoko Kawai, Makoto Nagamata & Yukio Hosomi. (2021)
Premature phase
II
study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
. Thoracic Cancer 12:11, pages 1668-1672.
Crossref
Crossref
Marika Cinausero, Karim Rihawi, Francesco Cortiula, Alessandro Follador, Gianpiero Fasola & Andrea Ardizzoni. (2019) Emerging therapies in malignant pleural mesothelioma. Critical Reviews in Oncology/Hematology 144, pages 102815.
Crossref
Crossref
Alexander M. Cryer & Andrew J. Thorley. (2019) Nanotechnology in the diagnosis and treatment of lung cancer. Pharmacology & Therapeutics 198, pages 189-205.
Crossref
Crossref
Keith M. Skubitz, Anne H. Blaes, Suma H. Konety & Gary S. Francis. (2017) Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value. Cancer Chemotherapy and Pharmacology 80:4, pages 787-798.
Crossref
Crossref
Marjorie G. Zauderer. 2017. Asbestos and Mesothelioma. Asbestos and Mesothelioma
313
345
.
Deniz Ali Bölükbas & Silke Meiners. (2015) Lung cancer nanomedicine: potentials and pitfalls. Nanomedicine 10:21, pages 3203-3212.
Crossref
Crossref
Aaron S. Mansfield, James T. Symanowski & Tobias Peikert. (2014) Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials. Lung Cancer 86:2, pages 133-136.
Crossref
Crossref
Ahmad Raza, Blake A. Jacobson, Adam Benoit, Manish R. Patel, Joe Jay-Dixon, Hiroshi Hiasa, David M. Ferguson & Robert Arthur Kratzke. (2011) Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis. Investigational New Drugs 30:4, pages 1443-1448.
Crossref
Crossref
Ó Arrieta, L A Medina, E Estrada-Lobato, N Hernández-Pedro, G Villanueva-Rodríguez, L Martínez-Barrera, E O Macedo, V López-Rodríguez, D Motola-Kuba & J F Corona-Cruz. (2012) First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. British Journal of Cancer 106:6, pages 1027-1032.
Crossref
Crossref
Arun K. Iyer, Yang Su, Jinjin Feng, Xiaoli Lan, Xiaodong Zhu, Yue Liu, Dongwei Gao, Youngho Seo, Henry F. VanBrocklin, V. Courtney Broaddus, Bin Liu & Jiang He. (2011) The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma. Biomaterials 32:10, pages 2605-2613.
Crossref
Crossref
Ahad A. Sadiq, Manish R. Patel, Blake A. Jacobson, Marco Escobedo, Keith Ellis, Lisa M. Oppegard, Hiroshi Hiasa & Robert A. Kratzke. (2009) Anti-proliferative effects of simocyclinone D8 (SD8), a novel catalytic inhibitor of topoisomerase II. Investigational New Drugs 28:1, pages 20-25.
Crossref
Crossref
Rebecca Solomon & Alberto A. Gabizon. (2008) Clinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal Doxorubicin. Clinical Lymphoma and Myeloma 8:1, pages 21-32.
Crossref
Crossref
Mika A. Sovak, Seena C. Aisner & Joseph Aisner. 2008. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1367
1398
.
T. Berghmans, J.-M. Bréchot, G. Robinet, J. Guigay & P. Morère. (2006) 4.2. Chimiothérapie du mésothéliome pleural malin. Revue des Maladies Respiratoires 23:4, pages 57-70.
Crossref
Crossref
Shirish M. Gadgeel & Harvey I. Pass. (2006) Malignant mesothelioma. Community Oncology 3:4, pages 215-224.
Crossref
Crossref
Patricia J. Hollen, Richard J. Gralla, Astra M. Liepa, James T. Symanowski & James J. Rusthoven. (2005) Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso. Supportive Care in Cancer 14:1, pages 11-21.
Crossref
Crossref
Lee M. Krug. (2005) An Overview of Chemotherapy for Mesothelioma. Hematology/Oncology Clinics of North America 19:6, pages 1117-1136.
Crossref
Crossref
Jon Jones, Hasan Otu, Dimitrios Spentzos, Shakirahmed Kolia, Mehmet Inan, Wolf D. Beecken, Christian Fellbaum, Xuesong Gu, Marie Joseph, Allan J. Pantuck, Dietger Jonas & Towia A. Libermann. (2005) Gene Signatures of Progression and Metastasis in Renal Cell Cancer. Clinical Cancer Research 11:16, pages 5730-5739.
Crossref
Crossref
Nick Pavlakis & Nicholas J. Vogelzang. 2005. Malignant Mesothelioma. Malignant Mesothelioma
607
615
.
David S. Alberts, Franco M. Muggia, James Carmichael, Eric P. Winer, Mohammad Jahanzeb, Alan P. Venook, Keith M. Skubitz, Edgardo Rivera, Joseph A. Sparano, Nicholas J. Dibella, Simon J. Stewart, John J. Kavanagh & Alberto A. Gabizon. (2004) Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials. Seminars in Oncology 31, pages 53-90.
Crossref
Crossref
Amy S. Clark & Linda T. Vahdat. (2004) Chemotherapy-Induced Palmar-Plantar Erythrodysesthesia Syndrome: Etiology and Emerging Therapies. Supportive Cancer Therapy 1:4, pages 213-218.
Crossref
Crossref
Khaled Greish, Jun Fang, Takao Inutsuka, Akinori Nagamitsu & Hiroshi Maeda. (2003) Macromolecular Therapeutics. Clinical Pharmacokinetics 42:13, pages 1089-1105.
Crossref
Crossref
Giuseppe Giaccone & Egbert Smit. 2003.
445
483
.